Research
At the annual National ALS Registry Research Symposium, hosted by the Centers for Disease Control and Prevention (CDC), there was a special presentation on mapping to better understand the registry’s…
The viral ALS Ice Bucket Challenge a few years ago raised major funding that resulted in the discovery of new genes connected to the disease. One of those genes is…
On Wednesday, September 27, 2023, the FDA will host a public advisory committee meeting (AdComm) for BrainStorm Cell Therapeutics’ stem cell therapy NurOwn for the treatment of ALS. The public…
Expanding access to clinical trials is crucial to making ALS livable for everyone, everywhere, until we find a cure. One way to help make that a reality is by making…
To find new treatments and a cure for ALS, it’s vital to have a dedicated network of scientists working to advance our understanding of the disease and thinking creatively about…
This last year has seen incredible progress in the fight to create a world without ALS. The FDA approval of Relyvrio (AMX0035) in 2022 and Qalsody (tofersen) last month are…
A first-of-its-kind stem cell therapy for ALS passes a critical safety benchmark, advancing the search to slow down, reverse and prevent the disease. In a parallel study, investigators are growing…
On April 25, 2023, the US Food and Drug Administration (FDA) announced that Qalsody (tofersen) HAS BEEN APPROVED as a new prescription therapy for the treatment of people with rare…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for…
Since 1996, the Sheila Essey Award for ALS Research has been presented to acknowledge and honor an individual who is making significant contributions and breakthroughs in the search for the…